<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04526223</url>
  </required_header>
  <id_info>
    <org_study_id>HSCT-MF-01</org_study_id>
    <nct_id>NCT04526223</nct_id>
  </id_info>
  <brief_title>Outcomes of MF Patients Exposure to Ruxolitinib During Transplantation</brief_title>
  <official_title>Allogeneic HCT Outcomes in MF Patients Exposure to Ruxolitinib During Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>xuna</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nanfang Hospital of Southern Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Increasing experience of Ruxolitinib pre-allo SCT and data concerning Ruxolitinib during&#xD;
      transplantation&#xD;
&#xD;
        1. Diagnosis MF(includ Post-ET,Post-PV,PMF)&#xD;
&#xD;
        2. With at least two month Ruxolitinib treatment prior to transplantation&#xD;
&#xD;
        3. DAC+BF as myeloablative conditioning regimen&#xD;
&#xD;
        4. CSA from day -3 and MMF from day +1 until day 28 ATG Neovii® at dose of 7.5mg/KG for&#xD;
           mismatch donor&#xD;
&#xD;
        5. received Rux at +6d in ASCT and continued to +60d&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 20, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 20, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time of neutrophils reconstruction</measure>
    <time_frame>1 year</time_frame>
    <description>Neutrophils count≧0.5G/L without G-CSF</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The incidence rate of GVHD</measure>
    <time_frame>1 year</time_frame>
    <description>The incidence rate of aGVHD and cGVHD</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Time of Hematopoietic Reconstruction</condition>
  <arm_group>
    <arm_group_label>treatment group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MF patients exposure to ruxolitinib during transplantation</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>comprehensive treatment regimen</intervention_name>
    <description>Diagnosis MF(includ Post-ET,Post-PV,PMF)&#xD;
With at least two month Ruxolitinib treatment prior to transplantation&#xD;
DAC+BF as myeloablative conditioning regimen&#xD;
received Rux at +5d in ASCT and continued to +60d</description>
    <arm_group_label>treatment group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age 18-60 years old, gender is not limited;&#xD;
&#xD;
          2. Diagnosis MF(includ Post-ET,Post-PV,PMF) according to 2016 WHO&#xD;
&#xD;
          3. With at least two month Ruxolitinib treatment before transplantation&#xD;
&#xD;
          4. Informed consent of the patient or his legal representative&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. HCT-CI score≥2&#xD;
&#xD;
          2. Woman who is pregnant or nursing&#xD;
&#xD;
          3. MPN Patients who have received allogeneic hematopoietic stem cell transplantation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>H Nanfang, doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nanfang Hospital of Southern Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>na J xu</last_name>
    <phone>8618620698390</phone>
    <phone_ext>0</phone_ext>
    <email>sprenaa@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>NanfangH</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510515</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>xu na, doctor</last_name>
      <phone>18620698390</phone>
      <email>sprenaa@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Barbui T, Tefferi A, Vannucchi AM, Passamonti F, Silver RT, Hoffman R, Verstovsek S, Mesa R, Kiladjian JJ, Hehlmann R, Reiter A, Cervantes F, Harrison C, Mc Mullin MF, Hasselbalch HC, Koschmieder S, Marchetti M, Bacigalupo A, Finazzi G, Kroeger N, Griesshammer M, Birgegard G, Barosi G. Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet. Leukemia. 2018 May;32(5):1057-1069. doi: 10.1038/s41375-018-0077-1. Epub 2018 Feb 27. Review.</citation>
    <PMID>29515238</PMID>
  </reference>
  <reference>
    <citation>Kröger N, Shahnaz Syed Abd Kadir S, Zabelina T, Badbaran A, Christopeit M, Ayuk F, Wolschke C. Peritransplantation Ruxolitinib Prevents Acute Graft-versus-Host Disease in Patients with Myelofibrosis Undergoing Allogenic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2018 Oct;24(10):2152-2156. doi: 10.1016/j.bbmt.2018.05.023. Epub 2018 May 22.</citation>
    <PMID>29800615</PMID>
  </reference>
  <reference>
    <citation>Shahnaz Syed Abd Kadir S, Christopeit M, Wulf G, Wagner E, Bornhauser M, Schroeder T, Crysandt M, Mayer K, Jonas J, Stelljes M, Badbaran A, Ayuketang Ayuk F, Triviai I, Wolf D, Wolschke C, Kröger N. Impact of ruxolitinib pretreatment on outcomes after allogeneic stem cell transplantation in patients with myelofibrosis. Eur J Haematol. 2018 Sep;101(3):305-317. doi: 10.1111/ejh.13099. Epub 2018 Jul 4.</citation>
    <PMID>29791053</PMID>
  </reference>
  <reference>
    <citation>Jagasia M, Zeiser R, Arbushites M, Delaite P, Gadbaw B, Bubnoff NV. Ruxolitinib for the treatment of patients with steroid-refractory GVHD: an introduction to the REACH trials. Immunotherapy. 2018 Apr;10(5):391-402. doi: 10.2217/imt-2017-0156. Epub 2018 Jan 10.</citation>
    <PMID>29316837</PMID>
  </reference>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>February 16, 2020</study_first_submitted>
  <study_first_submitted_qc>August 21, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 25, 2020</study_first_posted>
  <last_update_submitted>September 2, 2021</last_update_submitted>
  <last_update_submitted_qc>September 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Nanfang Hospital of Southern Medical University</investigator_affiliation>
    <investigator_full_name>xuna</investigator_full_name>
    <investigator_title>doctor</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

